Bypassing municipal bureaucracy, the elite healthcare execution firm calls on operational nonprofits in Central Florida and Duval County to secure immediate, privately funded grants...
MONTRÉAL, June 08, 2026 (GLOBE NEWSWIRE) -- On June 4, 2026, Saputo Inc. (TSX: SAP) (we, Saputo or the Company) issued its 2026 Saputo Promise Report, which highlights progress in key Environmental, Social, and Governance (ESG) priorities that support operational resilience, disciplined long-term growth, and sustainable value creation.
Three new limited-time flavors, limited collectible in-store giveaways, and exclusive digital content launch June 8FARMERS BRANCH, Texas, June 8, 2026 /PRNewswire/ -- Yogurtland, the...
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.Delivers up to 2x increase in...
Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /CNW/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...
Wendy's joins Illumination's Minions & Monsters with a custom menu lineup, exclusive collectibles and a drive-thru takeover in Los AngelesFresh Facts:Get ready to experience...
Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...
Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...
The addition of Scan Sverige to Einride's growing portfolio of customers highlights the rising demand for scalable, fossil-free freight solutions in high-volume supply chains...
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.